191 related articles for article (PubMed ID: 2672019)
1. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM
Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019
[TBL] [Abstract][Full Text] [Related]
2. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
Brosman SA
Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239
[TBL] [Abstract][Full Text] [Related]
3. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
4. Management of superficial transitional cell carcinoma of the bladder.
Fleischmann J; Goldberg G
Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
[TBL] [Abstract][Full Text] [Related]
5. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
Brosman S
Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
[No Abstract] [Full Text] [Related]
6. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
[No Abstract] [Full Text] [Related]
7. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
Barreto L; Csizer Z; Sparkes JD
Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667
[TBL] [Abstract][Full Text] [Related]
9. BCG for bladder cancer.
Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783
[No Abstract] [Full Text] [Related]
10. Intravesical therapy for superficial bladder cancer.
Malkowicz SB
Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
[TBL] [Abstract][Full Text] [Related]
11. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
Witjes WP; van der Meijden PM; Roos EP; Witjes JA; Steerenberg PA; Doesburg W; Debruyne FM
Prog Clin Biol Res; 1992; 378():59-67. PubMed ID: 1301587
[No Abstract] [Full Text] [Related]
12. Long-term results of intravesical therapy for superficial bladder cancer.
Lamm DL
Urol Clin North Am; 1992 Aug; 19(3):573-80. PubMed ID: 1636241
[TBL] [Abstract][Full Text] [Related]
13. Intravesical instillation of BCG in carcinoma in situ of the urinary bladder. EORTC protocol 30861. EORTC-GU Group.
Jakse G
Prog Clin Biol Res; 1989; 310():187-92. PubMed ID: 2771992
[TBL] [Abstract][Full Text] [Related]
14. Therapy of superficial bladder cancer.
Nseyo UO; Lamm DL
Semin Oncol; 1996 Oct; 23(5):598-604. PubMed ID: 8893870
[TBL] [Abstract][Full Text] [Related]
15. [Intravesical BCG therapy in patients with recurrent superficial bladder tumors].
Sugimoto M; Yamamoto H; Itakura H; Shinohara M; Kinoshita K
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3725-8. PubMed ID: 2596855
[TBL] [Abstract][Full Text] [Related]
16. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous, oral, or intravesical BCG administration: what is the optimal route?
Lamm DL; Sarodosy MS; DeHaven JI
Prog Clin Biol Res; 1989; 310():301-10. PubMed ID: 2672018
[No Abstract] [Full Text] [Related]
18. [Treatment and follow-up of superficial bladder cancer].
Raitanen M
Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
[No Abstract] [Full Text] [Related]
19. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
20. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
Demkow T; Alter A; Wiechno P
Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
